Andreas Kronbichler, Milena Bond, Christian Dejaco
doi : 10.1093/rheumatology/keac423
Rheumatology, Volume 62, Issue 3, March 2023, Pages 993–995
Jürgen Braun, Xenofon Baraliakos
doi : 10.1093/rheumatology/keac464
Rheumatology, Volume 62, Issue 3, March 2023, Pages 996–998
Sergio A Jimenez, Sonsoles Piera-Velazquez
doi : 10.1093/rheumatology/keac451
Rheumatology, Volume 62, Issue 3, March 2023, Pages 999–1008
SSc is a systemic autoimmune disease of unknown etiology characterized by frequently progressive cutaneous and internal organ fibrosis causing severe disability, organ failure and high mortality.
Tommy Harty, Michelle O’Shaughnessy, Sinead Harney
doi : 10.1093/rheumatology/keac460
Rheumatology, Volume 62, Issue 3, March 2023, Pages 1009–1020
The field of rheumatology has advanced significantly in recent years to provide rheumatologists with an extensive array of medications to combat rheumatic joint conditions.
Ioanna Minopoulou, Nikolaos Pyrgidis, Maksim Tishukov, Ioannis Sokolakis, Pantelis Baniotopoulos, Aristeidis Kefas, Michael Doumas, Georgios Hatzichristodoulou, Theodoros Dimitroulas
doi : 10.1093/rheumatology/keac457
Rheumatology, Volume 62, Issue 3, March 2023, Pages 1021–1030
In women with systemic autoimmune rheumatic diseases (SARDs), female sexual dysfunction (SD) remains underestimated. We aimed to explore the prevalence and correlates of SD in females with SARDs.
Honoria Ocagli, Roberto Agarinis, Danila Azzolina, Alen Zabotti, Elena Treppo, Andrea Francavilla, Patrizia Bartolotta, Federica Todino, Marco Binutti, Dario Gregori, Luca Quartuccio
doi : 10.1093/rheumatology/keac476
Rheumatology, Volume 62, Issue 3, March 2023, Pages 1031–1046
In the management of rheumatic musculoskeletal disorders (RMDs), regular physical activity (PA) is an important recognized non-pharmacological intervention. This systematic review and meta-analysis aims to evaluate how the use of wearable devices (WDs) impacts physical activity in patients with noninflammatory and inflammatory rheumatic diseases.
Vasiliki-Kalliopi Bournia, George E Fragoulis, Panagiota Mitrou, Konstantinos Mathioudakis, Anastasios Tsolakidis, George Konstantonis, Ioulia Tseti, Georgia Vourli, Maria G Tektonidou, Dimitrios Paraskevis, Petros P Sfikakis
doi : 10.1093/rheumatology/keac422
Rheumatology, Volume 62, Issue 3, March 2023, Pages 1047–1056
To investigate coronavirus disease 2019 (COVID-19)-associated risk of hospitalization and death in RA, AS, PsA, SLE and SSc in comparison with the general population during the first year of the pandemic, and compare their overall mortality with 2019.
Ilfita Sahbudin, Ruchir Singh, Paola De Pablo, Elizabeth Rankin, Benjamin Rhodes, Elizabeth Justice, Emma Derrett-Smith, Nicole Amft, Nehal Narayan, Catherine McGrath, Sangeetha Baskar, Jeanette Trickey, Mark Maybury, Karim Raza, Andrew Filer
doi : 10.1093/rheumatology/keac199
Rheumatology, Volume 62, Issue 3, March 2023, Pages 1057–1068
The value of US-defined tenosynovitis in predicting the persistence of inflammatory arthritis is not well described. In particular, the predictive utility of US-defined tenosynovitis of larger tendons is yet to be reported. We assessed the value of US-defined tenosynovitis alongside US-defined synovitis and clinical and serological variables in predicting persistent arthritis in an inception cohort of DMARD-naïve patients with early arthritis.
Miriam Almirall, Francesc Casellas, Joan Dot, Inés de Torres, Hegoi Segurola, Sara Marsal
doi : 10.1093/rheumatology/keac434
Rheumatology, Volume 62, Issue 3, March 2023, Pages 1069–1077
To establish the prevalence of non-coeliac gluten sensitivity (NCGS) in a cohort of fibromyalgia patients and to evaluate their clinical response to a six-week gluten-free diet (GFD), the improvement in their symptoms, the percentage of diet responders who did not fulfil the diagnostic criteria for NCGS and the baseline characteristics that were associated with diet response and diagnostic criteria fulfilment.
Sarah Tosato, Chiara Bonetto, Alice Zanini, Ilaria Montanari, Anna Piccinelli, Riccardo Bixio, Maurizio Rossini, Giulio Pacenza, Doriana Cristofalo, Elena Fracassi, Antonio Carletto
doi : 10.1093/rheumatology/keac445
Rheumatology, Volume 62, Issue 3, March 2023, Pages 1078–1086
Few data are available on the role of emotional distress as a possible mediator of the relationship between coping strategies and the Patient Global Assessment (PGA). This study aims to investigate, in a large cohort of patients affected by RA, the relationship between specific copying strategies and PGA, and the role of emotional distress as a mediator.
Jun Qiao, Sheng-Xiao Zhang, Min-Jing Chang, Ting Cheng, Jia-Qian Zhang, Rong Zhao, Shan Song, Guang-Ying Liu, Jia-Song Chang, Xiao-Feng Li
doi : 10.1093/rheumatology/keac458
Rheumatology, Volume 62, Issue 3, March 2023, Pages 1087–1096
The most used drug for the treatment of rheumatoid arthritis (RA) remains methotrexate (MTX). Unfortunately, up to 50% of patients do not achieve a clinically adequate outcome. Here we study whether the gut microbiota patterns can aid in the prediction of MTX efficacy for RA.
Kristine M Latocha, Katrine B Løppenthin, Mikkel Østergaard, Poul J Jennum, Merete L Hetland, Henrik Røgind, Tine Lundbak, Julie Midtgaard, Robin Christensen, Bente A Esbensen
doi : 10.1093/rheumatology/keac448
Rheumatology, Volume 62, Issue 3, March 2023, Pages 1097–1107
The primary objective was to compare the effect of cognitive behavioural therapy for insomnia (CBT-I) to usual care on sleep efficiency, measured by polysomnography (PSG) immediately after the intervention at week 7. Secondary objectives included comparing the longer-term effect on sleep- and RA-related outcomes at week 26.
Edoardo Cipolletta, Abhishek Abhishek, Jacopo Di Battista, Walter Grassi, Emilio Filippucci
doi : 10.1093/rheumatology/keac367
Rheumatology, Volume 62, Issue 3, March 2023, Pages 1108–1116
To evaluate whether US findings indicating MSU deposits and US-detected inflammation (i.e. power Doppler signal) predict gout flares over 12 months.
Katharina Ziegeler, Sevtap Tugce Ulas, Denis Poddubnyy, Fabian Proft, Valeria Rios Rodriguez, Judith Rademacher, Kay Geert A Hermann, Torsten Diekhoff
doi : 10.1093/rheumatology/keac282
Rheumatology, Volume 62, Issue 3, March 2023, Pages 1117–1123
To assess the impact of joint shape variations on inflammatory lesions on SI joint MRIs in patients with axial spondyloarthritis (axSpA).
John A Reynolds, Mary Gayed, Munther A Khamashta, Francesca Leone, Veronica Toescu, Ian N Bruce, Ian Giles, Lee-Suan Teh, Neil McHugh, Mohammed Akil, Christopher J Edwards, Caroline Gordon
doi : 10.1093/rheumatology/keac372
Rheumatology, Volume 62, Issue 3, March 2023, Pages 1124–1135
HCQ and AZA are used to control disease activity and reduce risk of flare during pregnancy in patients with SLE. The aim of this study was to determine the outcomes of children born to mothers with SLE exposed to HCQ or AZA during pregnancy and breast-feeding.
MarÃa Fernanda Zavala-Miranda, Abril Alicia Perez-Arias, SofÃa E Márquez-Macedo, Roque A Comunidad-Bonilla, Juanita Romero-Diaz, Luis E Morales-Buenrostro, Juan M MejÃa-Vilet
doi : 10.1093/rheumatology/keac407
Rheumatology, Volume 62, Issue 3, March 2023, Pages 1136–1144
To characterize the clinical presentation and outcomes of LN in a Hispanic cohort from Mexico.
Xiaochan Chen, Xiaowei Shi, Han Xue, Honghua Lv, Lishi Yu, Xiudi Wu, Qiaohong Wang, Huaxiang Wu, Fei Han, Jing Xue
doi : 10.1093/rheumatology/keac471
Rheumatology, Volume 62, Issue 3, March 2023, Pages 1145–1152
To investigate the efficacy and safety of rituximab (RTX) maintenance therapy compared with traditional immunosuppressive agent (ISA) maintenance therapy in patients with relapsing or refractory SLE.
Kai Zhang, Yuan An, Peng Zhao, Bo Huang, Yifan Wang, Xingyu Zhou, Gong Cheng, Xiaoyan Xing, Naidi Wang, Ruiling Feng, Siyue Yu, Min Li, Jing He, Zhanguo Li
doi : 10.1093/rheumatology/keac419
Rheumatology, Volume 62, Issue 3, March 2023, Pages 1153–1161
To identify predictors for lupus low disease activity state (LLDAS), early-achieved LLDAS and long-term disease activity, and to refine a prognostic stratification tool for use in active SLE patients.
Irene Altabás-González, Iñigo Rúa-Figueroa, Francisco Rubiño, Coral Mouriño RodrÃguez, Iñigo Hernández-RodrÃguez, Raul Menor Almagro, Esther Uriarte Isacelaya, Eva Tomero Muriel, Tarek C Salman-Monte, Irene Carrión-Barberà , Maria Galindo, Esther M RodrÃguez Almaraz, Norman Jiménez, Luis Inês, José Maria Pego-Reigosa
doi : 10.1093/rheumatology/keac462
Rheumatology, Volume 62, Issue 3, March 2023, Pages 1162–1169
To apply the lupus low disease activity state (LLDAS) definition within a large cohort of patients and to assess the agreement between the LLDAS and the physician’s subjective evaluation of lupus activity.
Majd Bairkdar, Enoch Yi-Tung Chen, Paul W Dickman, Roger Hesselstrand, Helga Westerlind, Marie Holmqvist
doi : 10.1093/rheumatology/keac474
Rheumatology, Volume 62, Issue 3, March 2023, Pages 1170–1178
To conduct the first-ever nationwide, population-based cohort study investigating survival patterns of all patients with incident SSc in Sweden compared with matched individuals from the Swedish general population.
Jung Yoon Pyo, Sung Soo Ahn, Jason Jungsik Song, Yong-Beom Park, Sang-Won Lee
doi : 10.1093/rheumatology/keac267
Rheumatology, Volume 62, Issue 3, March 2023, Pages 1179–1186
This study applied the 2022 criteria for granulomatosis with polyangiitis (GPA) proposed by the ACR and EULAR (the 2022 ACR/EULAR criteria) to Korean patients with previously diagnosed GPA to investigate the number of patients who could be reclassified as having GPA.
Oscar Plunde, Elisabet Svenungsson, Giulia Ferrannini, Anders Franco-Cereceda, Magnus Bäck
doi : 10.1093/rheumatology/keac466
Rheumatology, Volume 62, Issue 3, March 2023, Pages 1187–1196
The antiphospholipid syndrome is defined by antiphospholipid antibodies (aPL) together with arterial and/or venous thromboembolism and/or obstetric morbidities.
Wenhan Huang, Dandan Chen, Zhongjie Wang, Feifeng Ren, Lei Luo, Jun Zhou, Dongmei Huang, Mengxue Tian, Hong Chen, Lin Tang
doi : 10.1093/rheumatology/keac429
Rheumatology, Volume 62, Issue 3, March 2023, Pages 1197–1203
This study aimed to investigate the relationship between serum superoxide dismutase (SOD) and interstitial lung disease (ILD) among patients with anti-melanoma differentiation-associated gene 5 antibody (MDA5)-positive DM.
Akira Yoshida, Minchul Kim, Masataka Kuwana, Naveen Ravichandran, Ashima Makol, Parikshit Sen, James B Lilleker, Vishwesh Agarwal, Sinan Kardes, Jessica Day, Marcin Milchert, Mrudula Joshi, Tamer Gheita, Babur Salim, Tsvetelina Velikova, Abraham Edgar Gracia-Ramos, Ioannis Parodis, Albert Selva O’Callaghan, Elena Nikiphorou, Tulika Chatterjee, Ai Lyn Tan, Arvind Nune, Lorenzo Cavagna, Miguel A Saavedra, Samuel Katsuyuki Shinjo, Nelly Ziade, Johannes Knitza, Oliver Distler, Hector Chinoy, Vikas Agarwal, Rohit Aggarwal, Latika Gupta, COVAD Study Group
doi : 10.1093/rheumatology/keac441
Rheumatology, Volume 62, Issue 3, March 2023, Pages 1204–1215
The assessment of physical function is fundamental in the management of patients with idiopathic inflammatory myopathies (IIMs).
Hanxiao You, Lei Wang, Jiajia Wang, Chengyin Lv, Lingxiao Xu, Fenghong Yuan, Ju Li, Min Wu, Shiliang Zhou, Zhanyun Da, Jie Qian, Hua Wei, Wei Yan, Lei Zhou, Yan Wang, Songlou Yin, Dongmei Zhou, Jian Wu, Yan Lu, Dinglei Su, Zhichun Liu, Lin Liu, Longxin Ma, Xiaoyan Xu, Yinshan Zang, Huijie Liu, Tianli Ren, Fang Wang, Miaojia Zhang, Wenfeng Tan
doi : 10.1093/rheumatology/keac450
Rheumatology, Volume 62, Issue 3, March 2023, Pages 1216–1226
Baozhen Huang, Xinning Wang, Yanlin Niu, Yuchuan Ding, Xiaolei Wang, Qingqing Tan, Yucong Li, Yuan Liu, Ying Chi, Yuan Wang, Zhixuan Zhou, Jianguo Li
doi : 10.1093/rheumatology/keac399
Rheumatology, Volume 62, Issue 3, March 2023, Pages 1227–1237
To evaluate the use of Janus kinase inhibitor (JAKi) in treating JDM and develop cytokine biomarkers of active disease.
Seda Kutluğ Ağaçkıran, Murat Sünbül, Zekeriya Doğan, Derya Kocakaya, Semih Kayacı, Haner Direskeneli, Fatma Alibaz-Oner
doi : 10.1093/rheumatology/keac452
Rheumatology, Volume 62, Issue 3, March 2023, Pages 1238–1242
Behçet’s disease (BD) is a unique systemic vasculitis mainly involving veins, in contrast to other vasculitides. Prior studies have shown that pulmonary arteries (PAs) have a similar structure to systemic veins.
Ramya Janardana, S N Amin, Liza Rajasekhar, Benzeeta Pinto, Chanakya Kodishala, Sumithra Selvam, Vineeta Shobha
doi : 10.1093/rheumatology/keac438
Rheumatology, Volume 62, Issue 3, March 2023, Pages 1243–1247
Rituximab (RTX) use early in the course of refractory idiopathic inflammatory myopathy (IIM) is not well studied. This study sought to determine the short-term efficacy of RTX in a registry-based cohort of refractory IIM.
Ai Li Yeo, Michelle Leech, Samar Ojaimi, Eric Morand
doi : 10.1093/rheumatology/keac437
Rheumatology, Volume 62, Issue 3, March 2023, Pages 1248–1253
Autoantibodies to ENA are frequently ordered during the workup of suspected autoimmune connective tissue diseases. There are no current guidelines for repeat test ordering. The objective of this study was to assess the utility of repeat ENA testing after an initial negative result.
George A Karpouzas, Bianca Papotti, Sarah R Ormseth, Marcella Palumbo, Elizabeth Hernandez, Cinzia Marchi, Francesca Zimetti, Matthew J Budoff, Nicoletta Ronda
doi : 10.1093/rheumatology/keac394
Rheumatology, Volume 62, Issue 3, March 2023, Pages 1254–1263
Excessive cholesterol accumulation in macrophages is the pivotal step underlying atherosclerotic plaque formation. We here explore factors in the serum of patients with RA, and mechanisms through which they interact with and influence cholesterol loading capacity (CLC) of macrophages.
Rachel Audo, Pauline Sanchez, Benjamin Rivière, Julie Mielle, Jian Tan, Cédric Lukas, Laurence Macia, Jacques Morel, Claire Immediato Daien
doi : 10.1093/rheumatology/keac454
Rheumatology, Volume 62, Issue 3, March 2023, Pages 1264–1271
To explore colonic mucosa integrity, tight junction proteins zonula occludens-1, occludin and claudin 2 were quantified by immunohistochemistry on colonic biopsies in 20 RA patients and 20 age- and sex-matched controls. Staining intensity was assessed by two blinded independent readers.
Sizheng Steven Zhao, Eftychia Bellou, Suzanne M M Verstappen, Michael J Cook, Jamie C Sergeant, Richard B Warren, Anne Barton, John Bowes
doi : 10.1093/rheumatology/keac403
Rheumatology, Volume 62, Issue 3, March 2023, Pages 1272–1285
To examine associations between PsA and psoriasis vs lifestyle factors and comorbidities by triangulating observational and genetic evidence.
Ingrid A Szilagyi, Costanza L Vallerga, Cindy G Boer, Dieuwke Schiphof, M Arfan Ikram, Sita M A Bierma-Zeinstra, Joyce B J van Meurs
doi : 10.1093/rheumatology/keac415
Rheumatology, Volume 62, Issue 3, March 2023, Pages 1286–1295
The aim of this study was to identify biomarkers for radiographic OA severity and progression acting within the inflammation and metabolic pathways.
Mitsuhiro Akiyama, Keiko Yoshimoto, Sho Ishigaki, Katsuya Suzuki, Tsutomu Takeuchi, Yuko Kaneko
doi : 10.1093/rheumatology/keac391
Rheumatology, Volume 62, Issue 3, March 2023, Pages 1296–1305
T cells adhere to enthesis fibrocartilage via integrins and intrinsically require IL-17RA-mediated signals to maintain their effector function. We analysed CD29+IL-17RA+ T cells in inflamed lesions and peripheral blood in patients with SpA and investigated their association with disease activity and therapeutic response.
Joe E Mouawad, Shailza Sharma, Ludivine Renaud, Joseph M Pilewski, Satish N Nadig, Carol Feghali-Bostwick
doi : 10.1093/rheumatology/keac411
Rheumatology, Volume 62, Issue 3, March 2023, Pages 1306–1316
Lung fibrosis is the leading cause of death in SSc, with no cure currently available. Antifibrotic Endostatin (ES) production does not reach therapeutic levels in SSc patients, suggesting a deficit in its release from Collagen XVIII by the main cleavage enzyme, Cathepsin L (CTSL).
Paola Cipriani, Piero Ruscitti, Ilenia Di Cola, Marta Vomero, Franca Abbruzzese, Elena Di Nino, Rebecca Ross, Francesco Del Galdo, Roberto Giacomelli
doi : 10.1093/rheumatology/keac377
Rheumatology, Volume 62, Issue 3, March 2023, Pages 1317–1325
CD248 is a glycoprotein, highly expressed on pericytes and fibroblasts (FBs), that is implicated in the fibrotic process. During angiogenesis, CD248 can promote vessel regression, binding multimerin-2 (MMRN-2).
Naoki Mugii, Yasuhito Hamaguchi, Motoki Horii, Natsumi Fushida, Tomoyuki Ikeda, Kyosuke Oishi, Tetsutarou Yahata, Fujiko Someya, Takashi Matsushita
doi : 10.1093/rheumatology/keac401
Rheumatology, Volume 62, Issue 3, March 2023, Pages 1326–1334
To assess the longitudinal changes in nailfold videocapillaroscopy (NVC) in patients expressing myositis-specific autoantibodies [anti-aminoacyl-tRNA synthetase (ARS), anti-transcriptional intermediary factor 1 (TIF1), and anti-melanoma differentiation-associated gene 5 (MDA5)].
Haleigh Inthavong, Kamala Vanarsa, Jessica Castillo, M John Hicks, Chandra Mohan, Scott E Wenderfer
doi : 10.1093/rheumatology/keac465
Rheumatology, Volume 62, Issue 3, March 2023, Pages 1335–1342
The objective of this study was to evaluate the utility of urine CD163 for detecting disease activity in childhood-onset SLE (cSLE) patients.
Ashika Chhana, Bregina Pool, Karen E Callon, Dorit Naot, Ryan Gao, Brendan Coleman, Jillian Cornish, Geraldine M McCarthy, Nicola Dalbeth
doi : 10.1093/rheumatology/keac392
Rheumatology, Volume 62, Issue 3, March 2023, Pages 1343–1349
Basic calcium phosphate (BCP) crystals contribute to several syndromes associated with tendon disease, including acute calcific tendinitis and Milwaukee shoulder syndrome.
Lotte A van de Stadt, Féline P B Kroon, Christian F Thudium, Anne C Bay-Jensen, Margreet Kloppenburg
doi : 10.1093/rheumatology/keac442
Rheumatology, Volume 62, Issue 3, March 2023, Pages 1350–1355
To investigate whether biomarkers are modulated by prednisolone treatment in patients with hand OA and whether they can predict response to prednisolone.
doi : 10.1093/rheumatology/keac336
Rheumatology, Volume 62, Issue 3, March 2023, Page 1356
doi : 10.1093/rheumatology/keac449
Rheumatology, Volume 62, Issue 3, March 2023, Page 1357
doi : 10.1093/rheumatology/keac459
Rheumatology, Volume 62, Issue 3, March 2023, Pages e34–e35
Wenhan Huang, Feifeng Ren, Dandan Chen, Zhongjie Wang, Lin Tang
doi : 10.1093/rheumatology/keac475
Rheumatology, Volume 62, Issue 3, March 2023, Pages e36–e38
Boyuan Sun, Shuang Zhou, Huaxia Yang, Jiaxin Zhou, Xiaomei Leng, Wen Zhang, Xiaofeng Zeng
doi : 10.1093/rheumatology/keac436
Rheumatology, Volume 62, Issue 3, March 2023, Pages e39–e41
Aviya Lanis, Sadie Van Den Bogaerde, Yongdong Zhao
doi : 10.1093/rheumatology/keac461
Rheumatology, Volume 62, Issue 3, March 2023, Pages e42–e44,
Tajamul H Mir, Bushra Jabeen, Nisar A Wani, Bilal A Khan, Reem Javeed, M Omar Parvaiz
doi : 10.1093/rheumatology/keac424
Rheumatology, Volume 62, Issue 3, March 2023, Pages e45–e46
Augusta Ortolan, Stefania Vio, Mauro Gallo, Mariagrazia Lorenzin, Roberta Ramonda
doi : 10.1093/rheumatology/keac425
Rheumatology, Volume 62, Issue 3, March 2023, Page e47
Do you want to add Medilib to your home screen?